Investors

Latest Report

2017 - Q2 Quarterly Report

PROMETIC REPORTS 2017 SECOND QUARTER HIGHLIGHTS AND FINANCIAL RESULTS
$101 million of new 2017 cash inflows closed from debt, equity & corporate transactions
On-going review of plasminogen BLA with the U.S. FDA
48-week clinical data from plasminogen phase 2/3 trial confirms no recurrence of lesions, no safety or tolerability issues observed.
Concurrence from the FDA on the design of PBI-4050’s planned phase 2/3 pivotal clinical trial for Idiopathic Pulmonary Fibrosis
24-week clinical data confirm efficacy and safety of PBI-4050 maintained in metabolic syndrome & diabetic patients

Download

Annual Report

Annual Report 2016

Building a company to bring safer therapeutic products.

Download Link View all reports

Presentation

Prometic Corporate Presentation January 2017

Experts in bioseparation, plasma derived and small molecule drugs.

Download Link View all presentations
X